Expand ADAP Menu
ADAP MENU

ADAP Stock Summary and Trading Ideas (Adaptimmune Therapeutics PLC - American Depositary Shares | NASDAQ:ADAP)

Charts for Today's Stock Price and Implied Volatility in Adaptimmune Therapeutics PLC - American Depositary Shares

Stock Price & Volume | Full Chart

30-Day Implied Volatility | IV30 Full Chart

Trade Ideas for Best Option Strategies for ADAP by Theoretical Edge and Win Rates

Sentiment

Trading Statistics

Key Ratios

Adaptimmune Therapeutics PLC - American Depositary Shares (ADAP) Frequently Asked Questions

What does Adaptimmune Therapeutics PLC - American Depositary Shares do?

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

What symbol and exchange does Adaptimmune Therapeutics PLC - American Depositary Shares stock trade?

Adaptimmune Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol ADAP.

What is Adaptimmune Therapeutics PLC - American Depositary Shares stock price doing today?

As of March 31, 2023, ADAP stock price climbed to $1.08 with 220,751 million shares trading.

What is Adaptimmune Therapeutics PLC - American Depositary Shares's Beta?

ADAP has a beta of 1.84, meaning it tends to be more sensitive to market movements. ADAP has a correlation of 0.15 to the broad based SPY ETF.

How much is Adaptimmune Therapeutics PLC - American Depositary Shares worth?

ADAP has a market cap of $178.53 million. This is considered a Micro Cap stock.

How much money does Adaptimmune Therapeutics PLC - American Depositary Shares make?

Last quarter Adaptimmune Therapeutics PLC - American Depositary Shares reported $11 million in Revenue and -$.18 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.07.

What is the highest and lowest price Adaptimmune Therapeutics PLC - American Depositary Shares traded in the last 3 year period?

In the last 3 years, ADAP stock traded as high as $13.40 and as low as $1.01.

What are the top ETFs holding Adaptimmune Therapeutics PLC - American Depositary Shares?

The top ETF exchange traded funds that ADAP belongs to (by Net Assets): IBB, SPDW, GWX, BIB, IBBQ.

Is Adaptimmune Therapeutics PLC - American Depositary Shares (ADAP) a good investment?

ADAP has underperformed the market in the last year with a price return of -47.6% while the SPY ETF lost -9.8%. ADAP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.0% and -10.0%, respectively, while the SPY returned +6.9% and +3.6%, respectively.

What is the support and resistance for Adaptimmune Therapeutics PLC - American Depositary Shares (ADAP) stock price?

ADAP support price is $1.01 and resistance is $1.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADAP stock will trade within this expected range on the day.